[Superficial pyoderma requiring oral antibiotic therapy: fusidic acid versus pristinamycin]].
OBJECTIVE
This study was aimed to compare the clinical and antibacterial efficacy of fusidic acid 500 mg twice a day, per os, over 7.5 days) to pristinamycin 1 g twice a day, per os, over 10 days).


METHODS
Patients aged over 18, suffering from a superficial pyoderma requiring antibiotherapy and having given their informed consent were enrolled in a controlled, multicentre, double blind double dummy, parallel groups study. From day 0 to day 10, the patients received the randomised treatment. Those who were cured at day 11 had a visit at day 25 without any treatment between day 11 and day 25. A swab was performed on days 0, 11 and 25. The two treatment groups were compared in terms of efficacy, safety and global cost.


RESULTS
334 patients seen in dermatologic consultation were included in the study. 313 patients were analysed on an intent-to-treat basis. 158 received fusidic acid (FA) and 155 were treated with pristinamycin (P). At D11, 126 patients were cured in the FA group (79.7%) and 118 in the P group (76.1%) (p = 0.44). The bacteriological success rate was 85.2% in the FA group and 82.7 in the P group (p = 0.67). The recovery was confirmed in 92.6% of the FA patients and 90.4% of the P patients at D25 (p = 0.56). Digestive tolerance was better with fusidic acid than with pristinamycin. In economic terms, fusidic acid was cheaper than pristinamycin: 443 French francs in the FA group versus 545 FF in the P group.


CONCLUSIONS
Therefore we conclude that an oral course of 7.5 days with fusidic acid is an efficient and cheaper alternative to a treatment with pristinamycin over 10 days.
Service de Dermatologie, Hôpital Edouard Herriot, 5, place d'Arsonval, F 69437 Lyon Cedex 03.
A
A
Claudy
D000284:Administration, Oral; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000191:economics; D003365:Costs and Cost Analysis; D003627:Data Interpretation, Statistical; D004311:Double-Blind Method; D005260:Female; D005672:Fusidic Acid / Q000008:administration & dosage* / Q000191:economics; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011711:Pyoderma / Q000188:drug therapy*; D017192:Skin Diseases, Bacterial / Q000188:drug therapy*; D013207:Staphylococcal Skin Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy; D013997:Time Factors; D014769:Virginiamycin / Q000008:administration & dosage* / Q000191:economics
D000900:Anti-Bacterial Agents; D010919:Placebos; D014769:Virginiamycin; D005672:Fusidic Acid